Caricamento...
Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma
BACKGROUND: Merkel cell carcinoma (MCC) is a rare and aggressive neuroendocrine cutaneous malignancy with poor prognosis. In Europe, approved systemic therapies are limited to the PD-L1 inhibitor avelumab. For avelumab-refractory patients, efficient and safe treatment options are lacking. METHODS: A...
Salvato in:
| Pubblicato in: | Cancer Immunol Immunother |
|---|---|
| Autori principali: | , , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Springer Berlin Heidelberg
2021
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8195807/ https://ncbi.nlm.nih.gov/pubmed/33439294 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00262-020-02832-0 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|